Digest Network Come funziona
Network
/
Società
Co
Non verificato

Coya Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

47 comunicati stampa

Guarda tutti i comunicati
10/02/2026
Web e Social Network
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/01/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Finanza
Coya Therapeutics Announces $11.1 Million Private Placement
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Analisi di mercato
Industria
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Industria
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/11/2025
Eventi
Web e Social Network
Salute
Medicina - Varie
Scienza
Biotecnologia
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0